Comprehensive Financial Consultants Institutional Inc. Invests $780,000 in DexCom, Inc. (NASDAQ:DXCM)

Comprehensive Financial Consultants Institutional Inc. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,626 shares of the medical device company’s stock, valued at approximately $780,000.

Several other hedge funds have also bought and sold shares of DXCM. Advisors Asset Management Inc. grew its position in DexCom by 10.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 16,291 shares of the medical device company’s stock valued at $1,520,000 after purchasing an additional 1,588 shares during the period. Royal London Asset Management Ltd. grew its position in DexCom by 4.9% in the 3rd quarter. Royal London Asset Management Ltd. now owns 148,426 shares of the medical device company’s stock valued at $13,849,000 after purchasing an additional 6,954 shares during the period. Toroso Investments LLC grew its position in DexCom by 25.2% in the 3rd quarter. Toroso Investments LLC now owns 15,560 shares of the medical device company’s stock valued at $1,452,000 after purchasing an additional 3,127 shares during the period. TimesSquare Capital Management LLC grew its position in DexCom by 11,359.1% in the 3rd quarter. TimesSquare Capital Management LLC now owns 733,380 shares of the medical device company’s stock valued at $68,424,000 after purchasing an additional 726,980 shares during the period. Finally, Kampmann Melissa S. acquired a new stake in DexCom in the 3rd quarter valued at $3,538,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other DexCom news, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,102 shares of company stock worth $755,103. Company insiders own 0.30% of the company’s stock.

DexCom Stock Performance

DexCom stock traded down $0.13 during midday trading on Tuesday, reaching $110.84. The stock had a trading volume of 1,290,425 shares, compared to its average volume of 2,901,135. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The firm’s 50-day moving average price is $120.73 and its 200 day moving average price is $125.30. The firm has a market capitalization of $44.08 billion, a PE ratio of 71.51, a P/E/G ratio of 2.78 and a beta of 1.16. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. As a group, research analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Redburn Atlantic assumed coverage on DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 price objective on the stock. Raymond James raised their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. UBS Group raised their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $140.33.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.